$DCH

American Axle & Manufacturing’s (DCH) “Buy” Rating Reiterated at BWS Financial

BWS Financial reiterated a “buy” rating on American Axle & Manufacturing (DCH) and set a $17.00 price target, implying 192.85% upside from the prior close, according to Benzinga. Other firms issued mixed views, with RBC raising its target to $10 (“outperform”) and several downgrades to “hold” or “sell.” DCH traded at $5.80. The company reported $0.34 EPS on $2.38B revenue for the quarter.

Original reporting
Published Jun 25, 2026, 5:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 25, 2026, 5:57 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
American Axle & Manufacturing’s (DCH) “Buy” Rating Reiterated at BWS Financial — source image
Decision brief

The 30-second read

$DCHBullishLow
01

Why it matters

For traders, the actionable element is the new/renewed $17 target from BWS, which can influence short-term sentiment, but the broader rating mix and lack of new fundamentals constrain conviction.

02

Market read

Analyst-target momentum may support DCH near term, but the article does not introduce new fundamentals beyond the rating/target update.

03

What to watch

The piece provides no new operational development beyond analyst targets; without fresh guidance or contract/earnings updates, price reaction may fade quickly.

Relevance 4/10Novelty 4/10Timing: after-hours/next-session positioning following the Thursday analyst note

Background

The article summarizes BWS Financial’s reiterated “buy” and contrasts it with other broker rating changes, plus includes recent trading and last earnings figures.

Company-level read

Ticker impact

$DCHBullishMedium confidence
Context

BWS Financial reiterated a “buy” on American Axle & Manufacturing and set a $17 target, implying ~193% upside from the prior close.

Expected impact

Modest upside bias possible on analyst-target momentum, but likely capped by the broader consensus “Hold” and conflicting ratings.

Evidence & confidence

The article’s only new, company-specific catalyst is the reiterated buy with a specific $17 price target; it also notes consensus remains “Hold,” suggesting limited follow-through unless other brokers align.

Market effects

Limited read-across for auto parts/driveline peers; this is primarily single-name analyst-target momentum.

None indicated.

None indicated.

Counterpoint

The reiterated “buy” may be less actionable because the article highlights a consensus “Hold” and multiple recent holds/sell ratings.

Key entities

  • American Axle & Manufacturing

    US auto parts supplier; subject of the analyst rating reiteration and the stock/earnings snapshot in the article.

  • BWS Financial

    Equities research firm that reiterated a “buy” rating and set a $17 price target.

Related articles

$DCHMed

Dauch Corporation’s (DCH) Costly Path To A Bigger Payoff

Dauch Corporation (NYSE:DCH) reported Q2 sales of about $3B and adjusted EBITDA of $389.6M (13.2% of sales), citing integration progress after its Dowlais acquisition. It raised full-year guidance: sales $10.6B-$10.8B, adjusted EBITDA $1.36B-$1.425B, adjusted FCF $260M-$325M. Net interest expense rose to $82.6M and GAAP net income fell to $1M.

$DCHMedAI 8/10

Dauch (DCH) Q2 2026 Earnings Call Transcript

Dauch Corporation (DCH) held its Q2 2026 earnings call, reporting sales of $2.96B versus $1.54B prior year, boosted by $1.45B from the Dowlais acquisition. Adjusted EBITDA was $389.6M (13.2%) and adjusted free cash flow $148.4M. Full-year guidance: sales $10.6B-$10.8B and adjusted EBITDA $1.36B-$1.425B. Net leverage was 2.6x.

$DCHMedAI 8/10

American Axle & Manufacturing Q2 Earnings Call Highlights

American Axle & Manufacturing (DCH) reported Q2 adjusted EBITDA of $389.6M (13.2% of sales). It recorded $15M in quarterly synergy benefits and targets $100M+ by year-end. Cash from operations was $107.5M and adjusted free cash flow $148.4M. Full-year guidance raised: sales $10.6B-$10.8B and adjusted EBITDA $1.36B-$1.425B.

$DCHMed

Dauch Corp (DCH): Results of Operations and Financial Condition

Dauch Corp (DCH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Dauch Reports Second Quarter 2026 Financial Results Delivers Strong Performance and Operating Cash Flow DETROIT, August 7, 2026 -- Dauch Corporation ("Dauch") (NYSE: DCH; LSE: DCH) today reported its financial results for the second quarter 2026. Second Quarter 2026 Results • Sal

$DCHMedAI 9/10

Dauch Corporation (DCH) Reports Q1 2026 Sales Growth Amid Net Loss

Dauch Corp. (NYSE:DCH) reported Q1 2026 sales of $2.38 billion, up from $1.41 billion a year earlier, mainly attributed to its Dowlais Group acquisition. The company posted a net loss of $100.3 million ($0.52/share) but said Adjusted EBITDA was $308.5 million (13% of sales). Adjusted EPS rose to $0.34. For 2026, it projects sales of $10.3–$10.8 billion and Adjusted EBITDA of $1.3–$1.425 billion, expecting synergy benefits to exceed a $100 million run rate by year one.

$BNTXMed

BioNTech Ended a Cancer Vaccine Trial. What Does it Mean for its mRNA Strategy?

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.